Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Background Camrelizumab and chemotherapy demonstrated durable antitumor activity with
a manageable safety profile as first-line treatment in patients with advanced esophageal …

Immunotherapy has changed the treatment landscape for cancer over the past decade.
Inhibitors of the immune checkpoint proteins cytotoxic T lymphocyte antigen (CTLA)-4 …

Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

The gut microbiota modulates immune processes both locally and systemically. This
includes whether and how the immune system reacts to emerging tumours, whether …

Importance Management of checkpoint inhibitor–induced immune-related adverse events
(irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental …

Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but
come with severe immune-related adverse events (irAEs). To prevent fatality or chronicity …

Background Current treatment guidelines for immune-mediated diarrhea and colitis (IMDC)
recommend steroids as first-line therapy, followed by selective immunosuppressive therapy …